Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Lung Transplant Rejection

Ali Mrad  1 , Rebanta K. Chakraborty  2
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Lung Transplant Rejection

Ali Mrad et al.
Free Books & Documents

Excerpt

The number of lung transplants annually in the United States and worldwide has increased recently. This is due to the systemization of nationwide databases and allocation, improved surgical techniques, and a new generation of immunosuppressants. However, lung transplantation recipients continue to have a high rate of short-term and long-term failure rates compared to other solid organs. The 5-year survival rate is reported at 58%.

Although postsurgical complications, vascular complications, and infections do contribute substantially to both early and late postoperative failure, transplant rejections are also commonly seen. Recently reported incidence rates vary between 50% acute rejection rate within 1 year and 45% chronic rejection incidence within 5 years posttransplant.

Based on the timeline of occurrence and diagnosis post-transplant, lung transplant rejection can be categorized into the following subtypes:

  1. Hyperacute transplant rejection: Within the first 24 hours

  2. Acute transplant rejection: Within the first week to the first year

  3. Chronic lung allograft dysfunction (CLAD): Within less than 1 year

PubMed Disclaimer

Conflict of interest statement

Disclosure: Ali Mrad declares no relevant financial relationships with ineligible companies.

Disclosure: Rebanta Chakraborty declares no relevant financial relationships with ineligible companies.

References

    1. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Lund LH, Meiser B, Stehlik J, International Society for Heart and Lung Transplantation The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014 Oct;33(10):1009-24. - PubMed
    1. Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P. A new classification system for chronic lung allograft dysfunction. J Heart Lung Transplant. 2014 Feb;33(2):127-33. - PubMed
    1. Yousem SA, Zeevi A. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol. 2012 Jul;36(7):987-92. - PubMed
    1. Masson E, Stern M, Chabod J, Thévenin C, Gonin F, Rebibou JM, Tiberghien P. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant. 2007 Jun;26(6):642-5. - PubMed
    1. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc. 2009 Jan 15;6(1):54-65. - PMC - PubMed

Publication types

LinkOut - more resources